Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Britain nearing vaccine deal with European Union - The Times

Published 27/03/2021, 01:01
Updated 27/03/2021, 14:50
© Reuters. FILE PHOTO: A woman holds a medical syringe and a small bottle labelled "Coronavirus COVID-19 Vaccine

(Reuters) - Britain is close to striking a vaccine deal with the European Union as soon as this weekend that will remove the threat of the bloc cutting off supplies, The Times reported on Saturday.

Under the agreement the EU will remove its threat to ban the export of Pfizer-BioNTech vaccines to Britain, it added.

In return, the British government will agree to forgo some long-term supplies of the Oxford-AstraZeneca vaccine that had been due to be exported from a factory in Holland run by AstraZeneca (NASDAQ:AZN)'s subcontractor Halix, the newspaper reported.

However, the EU has never threatened a ban on the export of vaccines, but has only said it could block on a case-by-case basis specific vaccine shipments to countries with higher vaccination rates or that do not export vaccines to the EU.

"We are only at the start of discussions with the UK. There are no talks over the weekend," an EU Commission source said on Saturday, adding that sending vaccines produced at Halix was not part of the talks.

A second EU source had previously said that the EU has no intention of sharing with Britain the vaccine substance from Halix, which is estimated to have already produced enough for about 15-20 million doses, and can produce the equivalent of 5 million shots per month.

The British government, Pfizer-BioNTech, and AstraZeneca were not immediately available for comment.

The EU's rebuff follows Britain's repeated refusal to share with Brussels AstraZeneca doses produced at two factories in the UK.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

On Friday, the European Medicines Agency approved the Halix production site in the Netherlands that makes the AstraZeneca vaccine and a facility in Marburg in Germany producing BioNTech/Pfizer shots.

The EU's clearing of the vaccine site comes as the union is banking on it boosting deliveries in the second quarter and accelerate the slow pace of inoculations in the bloc.

Europe's troubled vaccine rollout has led to a quarrel with Britain, which has imported 21 million doses made in the EU, according to an EU official. Britain says it did a better job negotiating with manufacturers and arranging supply chains.

The EU says that Britain should share more, notably to help make up the shortfall in contracted deliveries of AstraZeneca shots.

Brussels and London sought to cool tensions on Wednesday, declaring they were working "to create a win-win situation and expand vaccine supply for all our citizens".

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.